glp-1 safe Good News: Medications in Type 1 Diabetes Look and Promising Compounded GLP-1s: Why doctors worry

Estos frmacos, diseados para imitar la accin del pptido similar al glucagn tipo 1 (GLP-1, una hormona natural que regula el apetito y el control de la glucosa), han emergido como una herramienta prometedora en la lucha contra la obesidad

Skipping Doses: Both medications are weekly injections, so missing a dose can throw things off track

Particles or floaters: Hold the vial up to a light source and look carefully

If you notice any unexpected change to any aspect of your health, please seek help from a qualified healthcare professional immediately

Type 2 diabetes mellitus (DM2) affects a 13.8% of the Spanish population1 and its prevalence is expected to increase in the future.2 The presence of DM2 increases significantly the risk of cardiovascular events, chronic kidney disease (CKD), and premature death3,4 and as its prevalence increases it is expected to rise the incidence of microvascular and macrovascular complications.5 Until the last decade, the control of blood glucose, blood pressure, dyslipidemia, and the use of inhibitors of the renin-angiotensin system (iSRA) have been the only strategies available to reduce cardiovascular and renal risk in this population

Sanofi Headquarters: Paris, France Sanofi is kind of a leading healthcare and pharmaceutical company, offering a broad portfolio across diabetes, specialty care, and vaccines